Health Care · Pharmaceutical Preparations

IRWD IRONWOOD PHARMACEUTICALS INC SEC Filings & Insider Trading Activity 2026

company
CIK 1446847110 filings
Russell 2000

IRWD at a glance

IRONWOOD PHARMACEUTICALS INC (IRWD, SEC CIK 1446847) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding IRONWOOD PHARMACEUTICALS INC (IRWD) shares worth $296.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Gaskins Tammi L on November 16, 2026 of 5,919 shares at $4.81 per share.
  • In the last 90 days, IRWD insiders reported 0 open-market purchases ($0) and 1 open-market sale ($28K) on Form 4, a net sale of $28K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$296.2M
−15.7% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$28K
13F holders
28 funds
$296.9M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $133.0M, up $11.0M YoY, driven by LINZESS U.S. net-profit share
  • Operating margin 70.0% vs 61.8% YoY, with operating income $93.1M vs $75.5M
  • Apraglutide R&D $25.2M, up from $17.8M, the largest pipeline expense
  • Cash $86.4M; operating cash flow $130.8M, financing outflow $259.7M
  • STARS-2 recruiting; regulatory filing for apraglutide planned in 2029, subject to results

Risk Factors

  • No material risk-factor changes disclosed; Item 1A contains no substantive risk discussion
  • Partner concentration: AbbVie accounted for $132.1 million of $132.7 million accounts receivable
  • Regulatory and legal exposure: Ferring settlement requires remaining $5.0 million payment by December 31, 2026
  • Liquidity risk: cash declined to $86.4 million while revolving debt remained $325.0 million
  • Commercial concentration: LINZESS U.S. collaboration generated $344.2 million of nine-month revenue through AbbVie

AI summary of the IRWD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s operating update and financial results details

Item EX-99.1: Item EX-99.1

  • Raised 2026 LINZESS U.S. sales guidance to $1.20-$1.25B, signaling sustained demand and improved net pricing
  • Raised 2026 revenue guidance to $485-$510M and adjusted EBITDA above $350M, strengthening earnings expectations
Filed Oct 16, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO succession effective January 1, 2027: Tammi Gaskins replaces Thomas McCourt after his 17 years with Ironwood
  • Gaskins joins the Board, expanding director count from eight to nine; McCourt remains a director

Item EX-99.1: Item EX-99.1

  • Tammi Gaskins becomes CEO and joins the board effective January 1, 2027
  • Tom McCourt retires as CEO after 17 years, remaining on Ironwood’s board
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Raised 2026 guidance: LINZESS U.S. sales $1.15–$1.20B, revenue $460–$485M, adjusted EBITDA above $310M
  • Q2 LINZESS sales $282.3M, up 14%, supported by 4% demand growth and improved net pricing

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Ironwood’s recent business activities and quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed financial results and business update

AI summaries of IRWD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IRWD

Don't miss the next IRWD filing

  • Alerts as it files. A push when IRWD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IRWD, by share count.
  • Ask anything. An AI agent that reads every IRWD filing and answers with sources.

IRWD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gaskins Tammi LSellNov 16, 2026$4.81
DENNER ALEXANDER JASep 15, 2026-
Silber JeffreyAJul 20, 2026-
Silver RonaldSellJul 7, 2026$4.52
McHugh JulieAJun 16, 2026-
McHugh JulieSellJun 16, 2026$3.73
Moukheibir CatherineAJun 16, 2026-
Kessler Marla LAJun 16, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$351.4M$296.2M
Operating Income-$93.1M$98.5M
Net Income-$1.0B$880K$24.0M
Op. Margin-26.5%33.3%
Net Margin-0.3%8.1%
Balance Sheet
Total Assets$471.1M$350.9M$396.9M
Equity--$301.3M-$261.8M
ROE--0.3%-9.2%
Per Share
EPS$-6.45$0.01$0.15
Cash Flow
Operating CF-$103.5M$127.0M
CapEx$273K$142K$34K

Source: XBRL data in IRONWOOD PHARMACEUTICALS INC (IRWD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IRWD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IRWD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$296.9M
Q2 202628$346.3M
Q1 202628$265.4M
Q4 202524$230.4M
Q3 202526$86.0M
Q2 202527$42.7M
Q1 202526$73.9M
Q4 202423$207.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IRWD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KOct 16, 2026Analysis-
4Sep 17, 2026--
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 22, 2026--
4Jul 9, 2026--
8-KJun 18, 2026Analysis-
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
4Jun 17, 2026--
8-KJun 15, 2026Analysis-
8-KMay 21, 2026Analysis
4May 21, 2026-
8-KMay 13, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
4Mar 17, 2026--

Related Health Care companies

All Health Care →

IRWD SEC filings: frequently asked questions

Are IRWD insiders buying or selling?

In the last 90 days, IRONWOOD PHARMACEUTICALS INC (IRWD) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $28,470 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IRWD stock?

As of September 30, 2026, the largest IRONWOOD PHARMACEUTICALS INC (IRWD) holders among the 13F filers tracked by SignalX were BlackRock ($73.3 million), Renaissance Technologies LLC ($31.9 million), State Street Corp ($26.7 million), Vanguard Capital Management LLC ($26.3 million), AQR Capital Management ($23.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IRWD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.

What did IRWD report in its latest 8-K?

IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Ironwood’s recent business activities and quarter ended September 30, 2026.

What are the latest IRWD SEC filings?

IRONWOOD PHARMACEUTICALS INC (IRWD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 18, 2026.

What is IRWD's SEC CIK number?

IRONWOOD PHARMACEUTICALS INC (IRWD)'s SEC Central Index Key (CIK) is 1446847. EDGAR lists every IRWD filing under that number.

Ask anything about IRWD

The research agent reads IRWD's filings, financials, insider trades and 13F holders, then answers with sources.